
Healthcare · NSE / BSE
Founded in 2001 by Mr. Dhirajlal Kotadia, Sahajanand Medical Technologies Ltd. is a medical device company that focuses on advanced Class III and Class C/D devices used mainly in vascular and structural heart treatments. The company was the first in the world to receive CE certification for a drug-eluting stent with a biodegradable polymer called Infinnium. Its product range includes coronary stents and balloons for vascular interventions, technologies like TAVI and occluders for structural heart treatments, as well as renal stents and drug-coated balloons. The company operates R&D centres in India and Thailand and has a strong innovation base with over 100 granted patents and several pending applications. Its key products, including Supraflex Cruz, Hydra, and Cocoon, are supported by multiple clinical studies and are used in more than 76 countries. Sahajanand follows a global distribution strategy combining direct sales, hybrid models, and distributor partnerships across different markets. As of March 31, 2025, the company had over 1,400 employees along with consultants and contract staff supporting its operations.
Price Band
₹327 – ₹344
Issue Size
₹475 Cr
Lot Size
43 shares
GMP
+4.9%
Est. Listing
₹361
at current GMP
Subscribed
14.21x
overall
Open
15 Oct 2026
Close
19 Oct 2026
Allotment
21 Oct 2026
Refund
22 Oct 2026
Demat Credit
23 Oct 2026
Listing
23 Oct 2026
Overall Subscription
14.21x
Total Demand
QIB Multiplier
34.70x
Institutions & Funds
NII / HNI
14.64x
High Net-Worth
Retail (RII)
3.04x
Individual Bidders
Live bidding breakdown by institutional, non-institutional, and retail investors
| Category | Shares Offered | Shares Applied / Bid | Times Subscribed |
|---|---|---|---|
| QIB | 2,714,424 | 94,179,804 | 34.70x |
| NIB | 2,035,817 | 29,812,072 | 14.64x |
| HNIs(10L +) | 1,357,212 | 22,212,725 | 16.37x |
| HNIs (2-10L) | 678,606 | 7,599,347 | 11.20x |
| RETAIL | 4,750,241 | 14,431,531 | 3.04x |
| EMPLOYEES | 250,000 | 92,880 | 0.37x |
| Total | 11,786,300 | 168,328,359 | 14.21x |
Total unique applications received across retail and HNI tranches
| Category | Applications Reserved | Applications Received | Times Subscribed |
|---|---|---|---|
| RETAIL | 110,471 | 299,713 | 2.71x |
| EMPLOYEES | — | 1,460 | 0.00x |
| HNIs(10L +) | 2,255 | 7,355 | 3.26x |
| HNIs (2-10L) | 1,127 | 12,318 | 10.93x |
| Total Applications | 113,853 | 320,846 | 2.82x |
Track continuous institutional and retail bidding order books for all active issues on the ipo live subscription feed.
Sahajanand Medical Technologies Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹475.48 Crores. The shares are offered at a price band of ₹327 to ₹344 per equity share on NSE and BSE. Currently, grey market participants and retail investors are watching the bidding trend, premium movement, and anchor book demand with keen interest.
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 43 shares (approx. ₹14,792 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Allotment reconciliation will be managed by Link Intime India Private Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2026-10-23, while un-allotted funds or UPI block mandates will be released on 2026-10-22.
The latest Grey Market Premium (GMP) for Sahajanand Medical Technologies Limited IPO is ₹17 per equity share. Based on the upper price band of ₹327 to ₹344 per equity share, the estimated listing price is ₹361 (+4.9% expected listing gain).
With a lot size of 43 shares and current GMP of ₹17, the expected profit per application lot is approx ₹731 (+4.9% gain). Minimum application cost is approx ₹14,792.
The Sahajanand Medical Technologies Limited IPO aggregate issue size is ₹475.48 Crores with an equity price band set at ₹327 to ₹344 per equity share. The retail lot size is 43 shares requiring a minimum capital outlay of approx. ₹14,792.
Live subscription figures are compiled real-time from the NSE and BSE bidding engines. Currently, overall subscription is 14.21x (Retail: 3.04x, QIB: 34.70x, NII: 14.64x). You can track live multiples directly on our dedicated subscription page.
The basis of allotment will be published on the official registrar portal (Link Intime India Private Limited) and the BSE status verification website on or around 2026-10-21. Investors can verify status using PAN card or application number.
Sahajanand Medical Technologies Limited shares are scheduled to list on NSE and BSE on 2026-10-23.